Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacokinetics and Tolerability of Telavancin at Differing Dosing Regimens in Cystic Fibrosis Adults Admitted With Acute Pulmonary Exacerbations

NCT03172793 is registered in ClinicalTrials.gov with Joseph L. Kuti, PharmD as lead sponsor.

NCT NCT03172793
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03172793 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacokinetics and Tolerability of Telavancin at Differing Dosing Regimens in Cystic Fibrosis Adults Admitted With Acute Pulmonary Exacerbations
Lead sponsor
Joseph L. Kuti, PharmD
Phase
Phase 4
Overall status
Completed
Start date
August 8, 2017
Completion date
April 17, 2019
Enrollment
18 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis